Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-based chemoradiotherapy versus durvalumab after chemoradiotherapy in untreated locally advanced non-small cell lung cancer
2019-001222-98Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab and durvalumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Jun 2019; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-001222-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001222-98.